Nautilus Biotechnology (NAUT) Gains from Investment Securities (2021 - 2024)

Nautilus Biotechnology has disclosed Gains from Investment Securities across 4 years of filings, most recently posting -$84000.0 for Q4 2024.

• Gains from Investment Securities for Q4 2024 came in at -$84000.0, up 98.9% year-over-year; the trailing twelve-month figure through Dec 2024 was -$84000.0 (changed N/A YoY), and the FY2024 annual result was -$84000.0, changed N/A from the prior year.
• Gains from Investment Securities came in at -$84000.0 for Q4 2024 at Nautilus Biotechnology, up from -$7.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $26.3 million in Q4 2021 to a low of -$7.6 million in Q4 2023.
• The 4-year median for Gains from Investment Securities is $1.7 million (2022), against an average of $5.6 million.
• Across the five-year window, Gains from Investment Securities plunged 551.6% in 2023 and jumped 98.9% in 2024, its largest moves.
• Nautilus Biotechnology's Gains from Investment Securities stood at $26.3 million in 2021, then slumped by 93.58% to $1.7 million in 2022, then slumped by 551.6% to -$7.6 million in 2023, then surged by 98.9% to -$84000.0 in 2024.
• The last three Gains from Investment Securities figures came in at -$84000.0 (Q4 2024), -$7.6 million (Q4 2023), and $7.6 million (Q1 2023), per Business Quant data.